Rational combination of a MEK inhibitor, selumetinib, and the wnt/calcium pathway modulator, cyclosporin a, in preclinical models of colorectal cancer
Anna Spreafico, John J. Tentler, Todd M. Pitts, Aik Choon Tan, Mark A. Gregory, John J. Arcaroli, Peter J. Klauck, Martine C. McManus, Ryan J. Hansen, Jihye Kim, Lindsey N. Micel, Heather M. Selby, Timothy P. Newton, Kelly L. McPhillips, Daniel L. Gustafson, James V. DeGregori, Wells A. Messersmith, Robert A. Winn, S. Gail Eckhardt
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Rational combination of a MEK inhibitor, selumetinib, and the wnt/calcium pathway modulator, cyclosporin a, in preclinical models of colorectal cancer'. Together they form a unique fingerprint.